The problem of viral escape is a major challenge for those attempting to control an ongoing HIV-1 infection with AAV-delivered transgenes. This problem can be addressed by anticipating and blocking viral escape pathways. Alternatively one can target unvarying cellular proteins. In Project 4, we determine if antibodies targeting two HIV-1 coreceptors, CCRS and CXCR4, can safely control HIV-1 replication. MSM Protein Technologies, Inc. has proprietary technology for developing fully human antibodies that can recognize any CCRS or CXCR4 epitope, and for further improving these antibodies to obtain affinities in the picomolar range. We have generated antibodies against a range of chemokine receptors, using technology that we originally developed to study CCRS and CXCR4. However, antibodies recognizing chemokine receptors can interfere with appropriate immune function. It is therefore critical that antibodies targeting CCRS or CXCR4 are not themselves receptor agonists, and that anti-CXCR4 antibodies do not interfere with chemotaxis or signaling mediated by the CXCR4 ligand CXCL12/SDF-1a. We will therefore: 1) generate and characterize sets high affinity antibodies specific for CCRS, recognizing distinct and noncompeting epitopes, which do not agonize the receptor, but which efficiently inhibit HIV-1 infection. 2) determine if heterodimeric forms of these anti-CCRS antibodies more effectively neutralizing HIV-1 than any individual anti-CCRS antibody. 3) develop and improve an anti-CXCR4 antibody that efficiently inhibits replication of X4 and RSX4 HIV-1 isolates, but which does not compete with SDF1a binding to CXCR4. 4) evaluate the ability of these antibodies, delivered as AAV expressed transgenes, to control ongoing SHIV infections in rhesus macaques.
These aims will generate several very high affinity anti-CCRS and -CXCR4 antibodies that potently neutralize HIV-1 infection, and establish their ability to control viral replication in vivo.

Public Health Relevance

Recombinant AAV-delivered transgenes have the potential to supplement or even replace conventional combination anti-HIV-1 therapies, and have considerable advantages over these therapies. This project will evaluate the therapeutic utility of transgenes that target the obligate HIV-1 coreceptors CXCR4 and CCRS. In doing so, we will evaluate one approach for limiting viral escape from expressed transgenes, and develop therapeutics that can be used in human clinical trials.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RB-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Florida
United States
Zip Code
Martinez-Navio, José M; Fuchs, Sebastian P; Pedreño-López, Sònia et al. (2016) Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol Ther 24:76-86
Gardner, Matthew R; Fellinger, Christoph H; Prasad, Neha R et al. (2016) CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. J Virol 90:7822-32
Rashnonejad, Afrooz; Chermahini, Gholamhossein Amini; Li, Shaoyong et al. (2016) Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene. Mol Biotechnol 58:30-6
Xie, Jun; Burt, Daniel Robert; Gao, Guangping (2015) Adeno-associated virus-mediated microRNA delivery and therapeutics. Semin Liver Dis 35:81-8
Wang, Dan; Mou, Haiwei; Li, Shaoyong et al. (2015) Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. Hum Gene Ther 26:432-42
Fuchs, Sebastian P; Martinez-Navio, José M; Piatak Jr, Michael et al. (2015) AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLoS Pathog 11:e1005090
Gardner, Matthew R; Kattenhorn, Lisa M; Kondur, Hema R et al. (2015) AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519:87-91
Ahmed, Seemin S; Gao, Guangping (2015) Making the White Matter Matters: Progress in Understanding Canavan's Disease and Therapeutic Interventions Through Eight Decades. JIMD Rep 19:11-22
Wang, Dan; Gao, Guangping (2014) State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med 18:67-77
Quinlan, Brian D; Joshi, Vinita R; Gardner, Matthew R et al. (2014) A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120. J Virol 88:3353-8

Showing the most recent 10 out of 22 publications